Loading ...
Someoneinventedthe patent expire
Profits lossesresultingfrom patent expiry
Revenue lossesresultingfrom patent expiry
by injury(passive) caused bylansoprazole patent expiration
the riskresultingfrom patent expiration
them to lose market exclusivitycausingthem to lose market exclusivity
you to remove AbbVie from your radarmay have causedyou to remove AbbVie from your radar
a substantial loss of revenuecan causea substantial loss of revenue
sales to drop by more thancan causesales to drop by more than
to massive falls in sales of the original as generics steal market share etcleadsto massive falls in sales of the original as generics steal market share etc
to massive falls in sales of the originalleadsto massive falls in sales of the original
to massive fallsleadsto massive falls
to a loss in revenues of over USD 1bn ... EUR 734 m ... in 2008 ... due to generic sales erosionwill leadto a loss in revenues of over USD 1bn ... EUR 734 m ... in 2008 ... due to generic sales erosion
to a 60 - 70 per cent crash in drug pricesusually leadsto a 60 - 70 per cent crash in drug prices
to the introduction of new entrantsleadingto the introduction of new entrants
in limited generic competitionresultsin limited generic competition
to declining salesmay leadto declining sales
in particularcan resultin particular
earnings and revenues to declineto causeearnings and revenues to decline
to the increasing launch of generic drugsleadsto the increasing launch of generic drugs
within - patent competition(passive) caused bywithin - patent competition
to the introduction of new biosimilarswill leadto the introduction of new biosimilars
the overall sales risk(passive) caused bythe overall sales risk
to onesetto one
to massive revenue lossescan leadto massive revenue losses
the loss(passive) caused bythe loss
to the manufacturing of generic drugs , which can be leveraged by the generic manufacturesleadsto the manufacturing of generic drugs , which can be leveraged by the generic manufactures
to diminution of its market share ... but can not reasonably be considered either imminent or necessarily drastic as Keryx was the only company to apply for a new drug application and it was not yet approvedmay leadto diminution of its market share ... but can not reasonably be considered either imminent or necessarily drastic as Keryx was the only company to apply for a new drug application and it was not yet approved
to take place on october 15 , 2017is setto take place on october 15 , 2017
to price competitionthereby leadingto price competition
sales to decline , or new competition , which we 'll talk about in a second , or new drug launchescausingsales to decline , or new competition , which we 'll talk about in a second , or new drug launches
to the availability of highly similar , safe and effective biotech products that are more reasonably priced and more affordable for patients requiring treatment with such productsleadsto the availability of highly similar , safe and effective biotech products that are more reasonably priced and more affordable for patients requiring treatment with such products
nothinginventednothing
enough competition in the markethas ... causedenough competition in the market
to manufacturing of genericsleadingto manufacturing of generics
in a smallcausein a small
in the sluggish growth rate of the adalimumab market in Latin Americahas resultedin the sluggish growth rate of the adalimumab market in Latin America
in the sluggish growth rate of the adalimumab market in Latin Americahas resultedin the sluggish growth rate of the adalimumab market in Latin America
to a 35 % decrease in 2006 sales for depression drug Zoloft , Pfizer 's third - highest sellerledto a 35 % decrease in 2006 sales for depression drug Zoloft , Pfizer 's third - highest seller
for August 20 , 2020setfor August 20 , 2020
paincausingpain